Innovations In Clinical Neuroscience

MAR-APR 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/822795

Contents of this Issue

Navigation

Page 35 of 45

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 4 , N U M B E R 3 – 4 , M A R C H – A P R I L 2 0 1 7 ] 36 REFERENCES 1. Bernardis LL, Bellinger LL. The lateral hypothalamic area revisited: ingestive behavior. Neurosci Biobehav Rev. 1996;20:189–287. 2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573– 585. 3. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus- specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:322–327. 4. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18:9996– 10015. 5. Nambu T, Sakurai T, Mizukami K, et al. Distribution of orexin neurons in the adult rat brain. Brain Res. 1999;827:243–260. 6. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437:1257–1263. 7. Date Y, Ueta Y, Yamashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A. 1999;96:748–753. 8. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron. 2003;38:701–713. 9. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98:437–451. 10. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:469–474. 11. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30:345–354. 12. Hirota K, Kushikata T, Kudo M, et al. Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle- aged rats. Brain Res. 2003;981:143– 150. 13. Kayaba Y, Nakamura A, Kasuya Y, et al. Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol. 2003;285:R581– 593. 14. Al-Barazanji KA, Wilson S, Baker J, et al. Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats. J Neuroendocrinol. 2001;13:421–424. 15. Brunton PJ, Russell JA. Hypothalamic- pituitary-adrenal responses to centrally administered orexin-A are suppressed in pregnant rats. J Neuroendocrinol. 2003;15:633–637. 16. Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA. 1999;96:10911–10916. 17. Smart D, Haynes AC, Williams G, Arch JR. Orexins and the treatment of obesity. Eur J Pharmacol. 2002;440:199–212. 18. United States Food and Drug Administration FDA News Release: FDA Approves New Type of Sleep Drug. Belsomra. 2014. [Accessed March 17, 2015]. Available from:http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm 409950.htm. 19. Parker T. Merck enters the Insomnia market through the launch of Belsomra in Japan. 2014. [Accessed May 12, 2015]. GlobalData Website. Available from: http://healthcare.globaldata.com/resou rces/expert- insights/pharmaceuticals/merck- enters-the-insomnia-market-through- the-launch-of-belsomra-in-japan. 20. World Health Organization site. International Statistical Classification of Diseases and Related Health Problems 10th Revision. http://apps.who.int/classifications/icd1 0/browse/2016/en. Accessed 30 April 2017. 21. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. 22. Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD- 7. Arch Intern Med. 2006;166(10):1092–1097. 23. Spitzer RL, Kroenke K, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. 24. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biol Psychiatry. 2016;79:136–148. doi: 10.1016/j.biopsych.2014.10.003. 25. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo- controlled trial. Lancet Neurol. 2014;13:461–471. doi: 10.1016/S1474-4422(14)70053-5. 26. Russell SH, Kim MS, Small CJ, et al. Central administration of orexin A suppresses basal and domperidone stimulated plasma prolactin. J Neuroendocrinol. 2000;12:1213–1218. 27. Samson WK, Bagley SL, Ferguson AV, White MM. Hypocretin/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress. Am J Physiol Regul Integr Comp Physiol. 2007;292:R382–387. 28. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523–1631. 29. Chang YS, Chen HL, Wu YH, et al. Rotating night shifts too quickly may cause anxiety and decreased attentional performance, and impact prolactin levels during the subsequent day: a case control study. BMC Psychiatry. 2014;14:218. doi: 10.1186/s12888-014-0218-7. 30. Schwartz MW, Seeley RJ, Tschöp MH, et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature. 2013;503:59–66. doi: 10.1038/nature12709.

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2017